Cytokine‐Induced Memory‐Like NK Cells: Emerging strategy for AML immunotherapy - 11/11/23
, Abbas Hajifathali b, ⁎ , Ahmad Gharehbaghian c, d, ⁎, 1 Abstract |
Acute myeloid leukemia (AML) is a heterogeneous disease developed from the malignant expansion of myeloid precursor cells in the bone marrow and peripheral blood. The implementation of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT) has improved outcomes associated with AML, but relapse, along with suboptimal outcomes, is still a common scenario. In the past few years, exploring new therapeutic strategies to optimize treatment outcomes has occurred rapidly. In this regard, natural killer (NK) cell-based immunotherapy has attracted clinical interest due to its critical role in immunosurveillance and their capabilities to target AML blasts. NK cells are cytotoxic innate lymphoid cells that mediate anti-viral and anti-tumor responses by producing pro-inflammatory cytokines and directly inducing cytotoxicity. Although NK cells are well known as short-lived innate immune cells with non-specific responses that have limited their clinical applications, the discovery of cytokine-induced memory-like (CIML) NK cells could overcome these challenges. NK cells pre-activated with the cytokine combination IL-12/15/18 achieved a long-term life span with adaptive immunity characteristics, termed CIML-NK cells. Previous studies documented that using CIML-NK cells in cancer treatment is safe and results in promising outcomes. This review highlights the current application, challenges, and opportunities of CIML-NK cell-based therapy in AML.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | AML classic treatment approaches are faced with various challenges. |
• | NK cell-based therapeutic method has no life-threatening adverse events. |
• | CIML-NK cells with a long life are appreciated candidates for AML immunotherapy. |
• | CIML-NK cell-based therapy in AML patients is associated with promising outcomes. |
• | CIML-NK cell combination with CAR structure enhances their anti-cancer activities. |
Abbreviations : ADCC,, ADAM17,, ALL,, AML,, APL,, BiKE,, BM,, CAR,, cCR, CIML,, CHS,, CLL,, CMV,, Cri,, CRS,, c-Kit,, DLBCL,, DLI,, EBV,, GVHD,, FLT3,, HCV,, HBV,, hESC,, HSCT,, HLA-G,, HSV-2,, ICE,, iC9,, IDH,, IDO,, IL,, iPSC,, ITIM,, IL-2Rαβγ,, KIR,, LRA,, mAb,, MCMV,, MDSC,, MIC,, ml,, MLFS,, MM,, MRD,, NCR,, NHL,, NKG2DL,, NKG,, NKp,, NP,, ORR,, OS,, PB,, PGE2,, Prf1,, ref/rel,, RSV, scFv,, SEMA7A,, SIV,, sMICA,, TAM,, Treg,, TME,, TGF-β,, UCB,, ULBP, 2DG,
Keywords : Acute myeloid leukemia, NK cells, Cytokine-induced memory-like NK cells, Immunotherapy
Plan
Vol 168
Article 115718- décembre 2023 Retour au numéro
Article précédent
- Exosomes loaded with chondrogenic stimuli agents combined with 3D bioprinting hydrogel in the treatment of osteoarthritis and cartilage degeneration
- Hui Zhang, Jianghong Huang, Murad Alahdal
- Potential of cucurbitacin as an anticancer drug
- Yan Li, Yingrui Li, Yan Yao, Huayao Li, Chundi Gao, Changgang Sun, Jing Zhuang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?